Michael Schuster

Company: Mesoblast

Job title: Head of Pharma Partnering

Seminars:

Mesenchymal Precursor Cells for the Continuum of HFrEF From Class II/III Through End-Stage on LVADs 11:30 am

Intramyocardial MPC Phase 3 trial results showing reduction in CV death, MI and stroke in Class II/III HFrEF Patients Intramyocardial MLC Phase 2/3 trial results showing reduction in CV death and GI bleeding in Class IV ischemic HF patients requiring left ventricular assist device implantation Use of intravenous MLCs to reduce AAV dosage by 100-fold,…Read more

day: Conference Day 1